Mustang Bio, Inc.
MBIO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001680048
No open-market purchases or sales by Mustang Bio, Inc. insiders were filed in the last 90 days; 23 institutions reported holding it in 13F filings for Q2 2026, worth $378.3K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Mustang Bio, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Mustang Bio, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Litchman Manuel MD | President, CEO and Interim CFO | 1,615 | Apr 27, 2026 | 1 |
| Fortress Biotech, Inc. | 10% Owner | 536,577 | Jan 5, 2026 | 2 |
| Herskowitz Neil | Director | 145 | Dec 30, 2025 | 1 |
| Chill Adam J. | Director | 375 | Dec 30, 2025 | 1 |
| Jin David | Director | 286 | Dec 30, 2025 | 1 |
| Rosenwald Lindsay A MD | Director | 60,525 | Jul 7, 2023 | 0 |
| Weiss Michael S | Director | 49,637Indirect | Jul 7, 2023 | 0 |
| Zelefsky Michael J | Director | 18,970 | Jul 7, 2023 | 0 |
| Achenbach Brian | SVP, Fin. & Corp. Controller | 144,729 | Dec 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2025 (view filing) | Dec 30 | Same day | Herskowitz NeilDirector | SSaleCOMMON STOCK, PAR VALUE $0.0001 | −247 | $0.96 | −$237.12 | −63.0%145 after | |
| Dec 30, 2025 (view filing) | Dec 30 | Same day | Chill Adam J.Director | SSaleCOMMON STOCK, PAR VALUE $0.0001 | −4 | $0.95 | −$3.8 | −1.1%375 after | |
| Dec 30, 2025 (view filing) | Dec 30 | Same day | Jin DavidDirector | PPurchaseCOMMON STOCK, PAR VALUE $0.0001 | +247 | $0.96 | +$237.12 | +633.3%286 after | |
| Apr 3, 2023 (view filing) | Mar 18-Sep 13, 2022 | 381 daysLate | Litchman Manuel MDDirector | PPurchaseCOMMON STOCK, PAR VALUE $0.0001 | +10.0K | $0.63 | +$6.30K | +0.9%1.10M after | 2 lots |
| Apr 3, 2023 (view filing) | Mar 18-Sep 13, 2022 | 381 daysLate | Rosenwald Lindsay A MDDirector | PPurchaseCOMMON STOCK, PAR VALUE $0.0001 | +9.09K | $0.619 | +$5.63K | +3.1%299.2K after | 2 lots |
| Dec 16, 2021 (view filing) | Dec 14 | 2 days | Achenbach BrianSVP, Fin. & Corp. Controller | SSale | −4.37K | $1.83 | −$8.00K | −2.9%144.7K after | |
| Nov 8, 2021 (view filing) | Oct 27 | 12 daysLate | Litchman Manuel MDPresident and CEO | PPurchase | +65.0K | $2.24 | +$145.6K | +6.7%1.03M after | |
| Oct 21, 2021 (view filing) | Oct 12 | 9 daysLate | Achenbach BrianSVP, Fin. & Corp. Controller | SSale | −4.45K | $2.28 | −$10.1K | −3.4%126.6K after | |
| Aug 5, 2021 (view filing) | Jul 30 | 6 daysLate | Litchman Manuel MDPresident and CEO | PPurchase | +86.2K | $2.91 | +$250.9K | +9.9%960.2K after |